Close Menu

NEW YORK ─ Proteintech on Tuesday announced the acquisition of Munich-based ChromoTek, a manufacturer of single-domain antibodies, for an undisclosed amount.

The combined companies will better address growing opportunities and challenges in single-cell analysis, super-resolution imaging, and multiplex assays, and better serve research, translational science, and therapeutic applications, according to Chicago-based Proteintech, a manufacturer of antibodies, proteins, and immunoassays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.